Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$66.70 USD

66.70
5,600,365

+0.47 (0.71%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $66.69 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Medical Products' Earnings Roster for Oct 23: TMO, BSX & More

by Zacks Equity Research

Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.

Should You Buy Edwards Lifesciences (EW) Ahead of Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cerner (CERN) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Top-line growth, expected increase in bookings and solid show by Population Health, Revenue Cycle and IT Works are anticipated to get reflected in Cerner's (CERN) Q3 earnings.

What's in the Offing for Baxter's (BAX) Earnings in Q3?

by Zacks Equity Research

Baxter's (BAX) Q3 earnings is likely to have benefited from better-than-expected performance at Acute Therapies segment, solid product portfolio and anticipated rise in revenues.

What's in Store for Varian Medical (VAR) in Q4 Earnings?

by Zacks Equity Research

Varian (VAR) is expected to have gained from core Proton Therapy platform in fiscal Q4.

What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?

by Zacks Equity Research

The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.

Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mark Vickery headshot

Top Research Reports for Southern, Applied Materials & Vertex

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Southern Company (SO), Applied Materials (AMAT) and Vertex Pharmaceuticals (VRTX).

What's in Store for Intuitive Surgical (ISRG) in Q3 Earnings?

by Zacks Equity Research

Better-than-expected performance at Instruments & Accessories segment and da Vinci procedure growth are likely to aided Intuitive Surgical (ISRG) in Q3 earnings.

Edwards Lifesciences Hits a 52-Week High on Solid Prospects

by Zacks Equity Research

Edwards Lifesciences (EW) has been consistently delivering impressive results.

Will Edwards Lifesciences (EW) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT

by Zacks Equity Research

Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.

Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil

by Zacks Equity Research

Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil

What Makes Edwards Lifesciences (EW) a New Buy Stock

by Zacks Equity Research

Edwards Lifesciences (EW) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Tracey Ryniec headshot

Stock Investors: Do You Need a Late Cycle Plan?

by Tracey Ryniec

The financial media keeps talking about the economy being in the late cycle but that doesn't mean you can't be buying stocks.

Edwards Lifesciences Hits a 52-Week High on Solid Prospects

by Zacks Equity Research

Edwards Lifesciences (EW) gains from recent impressive developments.

Here's Why You Should Invest in Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edwards Lifesciences' (EW) performance.

Edwards Lifesciences Sapien 3 System Recall Classified Class I

by Zacks Equity Research

Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.

Why Is Edwards Lifesciences (EW) Up 3.2% Since Last Earnings Report?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Edwards Lifesciences' (EW) SAPIEN 3 TAVR Receives FDA Nod

by Zacks Equity Research

Edwards Lifesciences (EW) plans a commercial introduction of SAPIEN 3 Ultra in Europe.

HMS Holdings (HMSY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

HMS Holdings (HMSY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here is Why Growth Investors Should Buy Edwards Lifesciences (EW) Now

by Zacks Equity Research

Edwards Lifesciences (EW) could produce exceptional returns because of its solid growth attributes.

Edwards Lifesciences Corporation (EW) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Edwards Lifesciences Corporation (EW).

Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View

by Zacks Equity Research

Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.

Edwards Lifesciences (EW) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.76% and 4.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?